• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Century Therapeutics, Inc. - Common Stock (NQ:IPSC)

1.985 +0.025 (+1.28%)
Streaming Delayed Price Updated: 9:49 AM EDT, Aug 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Century Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
IN8bio's Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data ↗
January 22, 2024
IN8bio (NASDAQ: INAB) is a biotechnology company that specializes in developing novel therapies based on gamma-delta T cells. Its innovative technology focuses on harnessing the potential of these... 
Via Benzinga
News headline image
Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks Popping Over 80% In December ↗
December 19, 2023
Amidst fanfare for Nasdaq 100, U.S. small-cap stocks rally, with Russell 2000 index reaching levels not seen since Aug. 2022, 80% of stocks trading above 50-day MA, outperforming large caps &... 
Via Benzinga
Topics ETFs
News headline image
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
December 09, 2023
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Recap: Century Therapeutics Q3 Earnings ↗
November 09, 2023
 
Via Benzinga
News headline image
Century Therapeutics: Q1 Earnings Insights ↗
May 11, 2023
 
Via Benzinga
News headline image
Analyst Ratings for Century Therapeutics ↗
April 13, 2023
 
Via Benzinga
News headline image
Century Therapeutics's Return On Capital Employed Overview ↗
March 20, 2023
 
Via Benzinga
News headline image
Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus
December 06, 2023
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus
December 06, 2023
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential ↗
December 05, 2023
Although speculative ideas tend to be losers more so than winners, these 10-bagger penny stocks might tempt the gambler. 
Via InvestorPlace
News headline image
Where Century Therapeutics Stands With Analysts ↗
March 16, 2023
 
Via Benzinga
News headline image
Harnessing The Power Of Gamma-Delta T Cells In Cancer Therapy: IN8bio's Innovative Approach ↗
November 27, 2023
Why Are Gamma-Delta T Cells Important In Fighting Cancer? 
Via Benzinga
News headline image
Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 09, 2023
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases
November 09, 2023
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer
November 09, 2023
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits at the 65th ASH Annual Meeting and Exposition
November 02, 2023
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference
September 26, 2023
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023 ↗
August 28, 2023
 
Via Benzinga
News headline image
Workday To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Monday ↗
August 28, 2023
Truist Securities raised the price target for Church & Dwight Co., Inc. (NYSE: CHD) from $95 to $105. Truist Securities analyst Bill Chappell upgraded the stock from Hold to Buy. Church & Dwight shares... 
Via Benzinga
News headline image
These Analysts Slash Their Forecasts On Century Therapeutics After Weak Q2 Results ↗
August 10, 2023
Century Therapeutics, Inc. (NASDAQ: IPSC) reported weaker-than-expected second-quarter results. 
Via Benzinga
News headline image
Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 09, 2023
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
May 11, 2023
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit
April 17, 2023
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Announces Leadership Changes
April 12, 2023
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates
March 16, 2023
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at the AACR Annual Meeting 2023
March 15, 2023
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at Upcoming Investor Conferences
February 21, 2023
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas
February 08, 2023
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at Upcoming Investor Conferences
February 01, 2023
From Century Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap